Intensive Surveillance for Women With Breast Cancer: A Multicenter Retrospective Study in Korea
- Author:
Sungmin PARK
1
;
Hyeong-Gon MOON
;
Jong Won LEE
;
Ku Sang KIM
;
Zisun KIM
;
So-Youn JUNG
;
Jihyoun LEE
;
Se Kyung LEE
;
Byung Joo CHAE
;
Sung Ui JUNG
;
Jung Whan CHUN
;
Jong-Ho CHEUN
;
Hyun Jo YOUN
Author Information
- Publication Type:Original Article
- From:Journal of Breast Cancer 2024;27(4):235-247
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study evaluated the effectiveness of different surveillance intensities on morbidity and mortality in women with breast cancer.
Methods:This retrospective study included patients who had undergone breast cancer surgery in the Republic of Korea between 2009 and 2011. The patients were divided into two groups based on the intensity of their postsurgical surveillance: intensive surveillance group (ISG) and less-intensive surveillance group. Surveillance intensity was measured based on the frequency and type of follow-up diagnostic tests conducted, including mammography, ultrasonography, computed tomography, magnetic resonance imaging, bone scans, and positron emission tomography scans.
Results:We included 1,356 patients with a median follow-up period of 121.2 months (range, 12.8–168.0 months). The analysis revealed no significant difference in the overall survival (OS) between the two groups within five years of surgery. However, patients with ISG exhibited significantly better breast cancer-specific survival (BCSS) and distant metastasisfree survival (DMFS) within the same period. Five years after surgery, the differences in survival outcomes between the groups were not statistically significant.
Conclusion:Intensive surveillance did not demonstrate a significant improvement in OS for patients with breast cancer beyond five years postoperatively. However, within the first five years, intensive surveillance was associated with better BCSS and DMFS. These findings suggest that personalized surveillance strategies may benefit specific patient subsets, particularly in the early years after treatment. Further nationwide randomized studies are warranted to refine surveillance guidelines and optimize outcomes in patients with breast cancer.
